Biomedical subjects

S Iwarson

Publications and source records attributed to S Iwarson.

At least 163 records · Page 9Linked to original sources

PubMed1975

Trigger factors and HL-A antigens in chronic active hepatitis.

Forty-six patients with histologically verified chronic active hepatitis (CAH) were divided into three groups according to whether the CAH was virus-induced, drug-induced, or cryptogenic. The frequency of the HL-A antigens 1 and 8 was increased in the cryptogenic group while the other groups did not differ significantly from healthy controls. Autoantibodies were often found in high titres in the drug-induced and cryptogenic groups but were infrequent in the virus-induced group.

Adolescent↗

PubMed1975

A new antigen-antibody system. Clinical significance in long-term carriers of hepatitis B surface antigen.

A new antigen-antibody system was recently described in hepatitis B surface antigen (HBSAG(-positive sera. Despite indications of heterogeneity in specificity, the designations "e antigen" and "e antibodies" are used for the system as such in this articly. E'IGHT OF 17 long-term carriers of HBSAg with a histological picture of chronic persistent hepatitis or chronic aggressive hepatitis carried the e antigen, while none had demonstrable e antibodies in serum. Ten of 12 healthy carriers with e antibodies were blood donors who had donated 95 units of blood; none of these carriers was associeated with a reported case of posttransfusion hepatitis. In five individuals in the incubation stage of hepatitis B, e antigen appeared simultaneously with HBSAg but before the rise in transaminase levels. This finding further links e antigen to hepatitis B.

Acute Disease↗

PubMed1975

Hepatitis B antigen and prevention of post-transfusion hepatitis B.

Screening for hepatitis B antigen (HB-sAg) in the serum of blood donors and exclusion of antigen-positive blood units have reduced the frequency of post-transfusion hepatitis but several cases of hepatitis B still occur in association with transfusions. One explanation for this is probably that HB-sAg is not an indicator of infectivity. Thus healthy carriers of the antigen seem to have low infectivity while carriers with chronic liver disease as well as donors incubating hepatitis B probably present a great risk.

Alanine Transaminase↗

PubMed1975

Hepatitis B immune serum globulin in prevention of hepatitis B among hospital personnel. Preliminary report from a controlled trial.

At Sahlgren Hospital, Göteborg, hepatitis B has been a serious problem for several years among the personnel in the hemodialysis and renal transplantation wards as well as in the chemical laboratories. For this reason a randomized controlled clinical study with conventional gammaglobulin and hepatitis B immune globulin was started in May 1973. The titer of anitbodies against HBsAg by passive hemagglutination was 1:100 and approximately 1:350,000, respectively. Newly employed staff without a history of jaundice and without demonstratable HBsAg (RIA) or HBsAb (RIP) in serum were enrolled in the trial. Assignment of the two preparations was performed by random numbers and the ampoules were labelled only with the serial number of the participant. Three cc of either preparation was administered i.m. within seven days after admission and was repeated three months later. After that no further injections were given. Each participating employee was followed up with liver function tests, IEOP, RIA and RIP tests for at least six months after the last injection. Preliminary results from this double-blind study, which is still going on, are presented.

Clinical Trials as Topic↗

PubMed1974